cabozantinib,pembrolizumab
merck,exelixis
['pembro', 'cabozantinib', 'exelixis', 'exelixisinc']
 updates: flagship molecule, cabozantinib, in combination with pembrolizumab, achieved the primary endpoint of orr in phase ii #clinicaltrial. pembrolizumab is approved for recurrent/metastatic hnscc treatment. learn more: #asco #asco22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry